Peter has more than 30 years of process development experience in the biopharmaceutical industry, including cell and gene therapies. During those years, he was involved in bringing more than 16 products to commercialization. Before joining Evox, he was Executive Director, Process Development at Autolus Therapeutics, where he led late-stage CMC activities for the AUTO1 (obe-cel) CD19 CAR T cell therapy program. Prior to that, Mr. Jones held several positions of increasing responsibility at Oxford Biomedica, including Senior Director, Head of Operational Strategy, Head of Technical Operations, and Head of Manufacturing Development supporting CMC-related activities for the Novartis’ CAR T cell therapy, Kymriah® and Orchard Therapeutics’ ADA-SCID gene therapy programs. Peter also served 20 years in multiple leadership roles spanning Discovery to Manufacturing at GlaxoSmithkline and Genzyme. Peter has a BSc in Applied Biology from the University of Hertfordshire and a MSc (Eng) in Biochemical Engineering from University College, London. He is also a chartered chemical engineer, Fellow of the Institution of Chemical Engineers and a Royal Academy of Engineering Visiting Professor in manufacturing of advanced therapies at Aston University.